Skip to main
TMO

TMO Stock Forecast & Price Target

TMO Analyst Ratings

Based on 18 analyst ratings
Buy
Strong Buy 33%
Buy 61%
Hold 6%
Sell 0%
Strong Sell 0%

Bulls say

Thermo Fisher Scientific is projected to experience a compound annual revenue growth rate of 5.4% in its Lab Products and Services segment over the next three years, despite a decline from the previous five-year period's growth of 16.9%. The company's expansion includes a significant acquisition, Clario, valued at $8.9 billion, which is expected to enhance its competitive position in the contract research organization (CRO) market, benefiting from increased outsourcing trends in biopharma clinical trials. Additionally, adjusted earnings per share (EPS) are anticipated to rise at an 8.5% compound annual rate over the next four years, indicating robust financial health and operational performance.

Bears say

Thermo Fisher Scientific experienced a significant decline in key financial metrics from 2021 to 2024, with adjusted EBIT margins falling by approximately 830 basis points to 22.6% and adjusted gross margins decreasing by 940 basis points to 42.2%, both metrics indicating worsening profitability. Additionally, the company's gross margins are now notably below levels achieved in 2019, further emphasizing a downward trend in financial performance. Compounding these concerns, funding for biotechnology projects in 2025 has started off slowly, with a 45% year-over-year decline in capital raised during the year's first half, suggesting potential challenges in future revenue growth.

TMO has been analyzed by 18 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 61% recommend Buy, 6% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Thermo Fisher Scientific and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Thermo Fisher Scientific (TMO) Forecast

Analysts have given TMO a Buy based on their latest research and market trends.

According to 18 analysts, TMO has a Buy consensus rating as of Dec 24, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $631, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $631, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Thermo Fisher Scientific (TMO)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.